- Home
- IKNA vs NTRB Comparison
IKNA vs NTRB Comparison
Compare IKNA & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- NTRB
- Stock Information
- Founded
- IKNA 2016
- NTRB 2016
- Country
- IKNA United States
- NTRB United States
- Employees
- IKNA N/A
- NTRB N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- IKNA Health Care
- NTRB Health Care
- Exchange
- IKNA Nasdaq
- NTRB Nasdaq
- Market Cap
- IKNA 61.8M
- NTRB 59.1M
- IPO Year
- IKNA 2021
- NTRB N/A
- Fundamental
- Price
- IKNA $1.36
- NTRB $7.50
- Analyst Decision
- IKNA Strong Buy
- NTRB Buy
- Analyst Count
- IKNA 1
- NTRB 1
- Target Price
- IKNA $4.00
- NTRB $13.00
- AVG Volume (30 Days)
- IKNA 95.6K
- NTRB 82.0K
- Earning Date
- IKNA 08-07-2025
- NTRB 05-30-2025
- Dividend Yield
- IKNA N/A
- NTRB N/A
- EPS Growth
- IKNA N/A
- NTRB N/A
- EPS
- IKNA N/A
- NTRB N/A
- Revenue
- IKNA N/A
- NTRB $2,398,437.00
- Revenue This Year
- IKNA N/A
- NTRB $560.75
- Revenue Next Year
- IKNA N/A
- NTRB $588.39
- P/E Ratio
- IKNA N/A
- NTRB N/A
- Revenue Growth
- IKNA N/A
- NTRB 18.92
- 52 Week Low
- IKNA $0.97
- NTRB $3.72
- 52 Week High
- IKNA $1.94
- NTRB $11.78
- Technical
- Relative Strength Index (RSI)
- IKNA 56.43
- NTRB 59.79
- Support Level
- IKNA $1.10
- NTRB $7.00
- Resistance Level
- IKNA $1.46
- NTRB $7.90
- Average True Range (ATR)
- IKNA 0.07
- NTRB 0.66
- MACD
- IKNA -0.00
- NTRB -0.01
- Stochastic Oscillator
- IKNA 57.58
- NTRB 37.45
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.